MarketInOut Stock Screener Log In | Sign Up

Enanta Pharmaceuticals Inc

IEX • Healthcare • Biotechnology • Quote as of 11/20/2026
Enanta Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization249.46 mln
Float27.75 mln
Earnings Date11/16/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-0.45
Highly suspicious

Relative Strength

6 / 100
Severely lagging

Debt / Equity

1.80
High leverage

Pre-Tax Margin

-97%
Severely loss-making

ROE

-64.75
Deeply negative

Business Description

Enanta Pharmaceuticals is a Massachusetts-based biotech company focused on creating small molecule treatments for viral infections and immune system disorders. Its drug pipeline covers a range of conditions, including hepatitis B and C, respiratory syncytial virus, COVID-19-related coronaviruses, chronic hives, and atopic dermatitis. The company works alongside Abbott Laboratories under a licensing agreement to develop and bring to market several hepatitis C treatments. Founded in 1995, Enanta continues to advance multiple therapies through various stages of clinical testing.

Key Fundamentals

EPS-2.35
ROE-64.75
RPS2.17
ROIC-40.57
ROA-20.60
Interest Cover-4.43
EBITDA, mln-45.31
EV / EBITDA-5.67
EV / EBIT-5.11
Revenue, mln65.26
EV / Revenue3.93

Quote Details

Last 7.62
Change -0.36 (-4.51%)
Open 7.82
Volume 373,552
Turnover 2,846,466
Average Volume 288,353

Financial Ratios

Pre-Tax Profit Margin-97
Leverage Ratio3.44
Current Ratio3.76
Price / Book2.61
Price / Tangible Book2.61
Debt / Equity1.80
Price / Sales3.72

Financial Strength

Altman Z-Score-0.9
Piotroski F-Score 4 / 9
Beneish M-Score-0.45
Short Ratio7.01
Short % of Float7.63

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -30.66% 3 / 100   
1 Month -34.42% 9 / 100   
2 Months -40.61% 14 / 100   
6 Months -45.38% 14 / 100   
1 Year -37.18% 22 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog